Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1649 1674 1675
This examiner grants 56% of resolved cases
Christina M. Borgeest is an examiner in Tech Center 1600 and Art Unit 1645, having resolved 725 cases. Her allowance rate of 55.6% indicates a more rigorous examination process than some of her peers. The interview lift of 21.4% is significant, suggesting that interviews are a highly effective way to increase the chances of an allowance. This 21.4% lift is a key strategic data point for practitioners facing rejections. The median days to allowance is 1159, which serves as a benchmark for the expected duration of successful prosecution.
With 725 resolved cases, the statistics offer a reliable view of her historical trends. The 55.6% allowance rate suggests a balanced outcome for applications. The interview lift is a practical tool for resolving issues. The 1159-day median provides a clear measure of her docket's pendency. This data from Art Unit 1645 offers valuable insights for managing the patenting process effectively and setting realistic expectations for the time to grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18008324 | ACVR1 (ALK2) RECEPTOR INHIBITION TO TREAT NEUROLOGICAL DISEASES | Final Rejection | The Regents of the University of California |
| 17554713 | Anti-CGRP Antibody Formulation | Non-Final OA | Eli Lilly and Company |
| 18272548 | POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION | Non-Final OA | WUXI BIOLOGICS IRELAND LIMITED |
| 18177566 | COMPOSITIONS AND METHODS FOR CROSSING BLOOD BRAIN BARRIER | Non-Final OA | California Institute of Technology |
| 18645005 | USE OF MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR CONTRACEPTION AND OVARIAN RESERVE PRESERVATION | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18250107 | BRAIN PENETRATING PEPTIDES | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17926668 | Screening method for effective target - E3 ligase combinations | Final Rejection | UMC Utrecht Holding B.V. |
| 17413772 | BIOMARKER COMBINATIONS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 18798878 | AFLIBERCEPT ATTRIBUTES AND METHODS OF CHARACTERIZING AND MODIFYING THEREOF | Non-Final OA | Amgen Inc. |
| 18038053 | QUANTIFICATION OF SPERM CENTRIOLE QUALITY | Final Rejection | The University of Toledo |
| 18511825 | RECOMBINANT TIM-4 PROTEIN, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DELIVERY SYSTEM AND METHODS OF MAKING AND USING SAME | Non-Final OA | Duke University |
| 18296763 | ADM2 GENE MARKER FOR DIAGNOSIS OR PROGNOSIS PREDICTION OF THYROID CANCER AND USES THEREOF | Final Rejection | The Industry & Academic Cooperation in Chungnam National University (IAC) |
| 18706717 | PEPTIDE HAVING PHYSIOLOGICAL ACTIVITIES AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 18592106 | BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH | Non-Final OA | Sera Prognostics, Inc. |
| 17945324 | METHODS OF USING ACTIVIN RECEPTOR TYPE IIA VARIANTS | Non-Final OA | Keros Therapeutics, Inc. |
| 18392612 | TREATMENT OF THE DEMENTIAS USING BOTULINUM TOXIN | Non-Final OA | Penland Foundation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy